Home > Research > Publications & Outputs > The efficacy of evolocumab in the management of...

Links

Text available via DOI:

View graph of relations

The efficacy of evolocumab in the management of hyperlipidemia: a systematic review

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

The efficacy of evolocumab in the management of hyperlipidemia: a systematic review. / Alhajri, Lamia; AlHadhrami, Asma; AlMheiri, Shama et al.
In: Therapeutic Advances in Cardiovascular Diseases, Vol. 11, No. 5-6, 01.05.2017, p. 155-169.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Alhajri, L, AlHadhrami, A, AlMheiri, S, AlMutawa, Y & AlHashimi, Z 2017, 'The efficacy of evolocumab in the management of hyperlipidemia: a systematic review', Therapeutic Advances in Cardiovascular Diseases, vol. 11, no. 5-6, pp. 155-169. https://doi.org/10.1177/1753944717698925

APA

Alhajri, L., AlHadhrami, A., AlMheiri, S., AlMutawa, Y., & AlHashimi, Z. (2017). The efficacy of evolocumab in the management of hyperlipidemia: a systematic review. Therapeutic Advances in Cardiovascular Diseases, 11(5-6), 155-169. https://doi.org/10.1177/1753944717698925

Vancouver

Alhajri L, AlHadhrami A, AlMheiri S, AlMutawa Y, AlHashimi Z. The efficacy of evolocumab in the management of hyperlipidemia: a systematic review. Therapeutic Advances in Cardiovascular Diseases. 2017 May 1;11(5-6):155-169. Epub 2017 Mar 20. doi: 10.1177/1753944717698925

Author

Alhajri, Lamia ; AlHadhrami, Asma ; AlMheiri, Shama et al. / The efficacy of evolocumab in the management of hyperlipidemia : a systematic review. In: Therapeutic Advances in Cardiovascular Diseases. 2017 ; Vol. 11, No. 5-6. pp. 155-169.

Bibtex

@article{385f75d0418346d4b434bea65e5666ea,
title = "The efficacy of evolocumab in the management of hyperlipidemia: a systematic review",
abstract = "Background: Hyperlipidemia or dyslipidemia has been a concern for a long time, with various guidelines emphasizing the importance of managing the lipid profile to prevent cardiac incidences. Although statins have been found to be highly effective, resistance and intolerability to side effects will continue to be a stumbling block for certain patients. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors tackle lipid profile via a novel mechanism and therefore provide an additional effective option for managing lipid profile. The overarching aim of this systematic review was to evaluate the efficacy of evolocumab among various populations with hypercholesterolemia. Methods: A comprehensive search was conducted in ProQuest Health & Medical Complete, Google Scholar, ScienceDirect, and PubMed to identify potential records; then titles, abstracts, and full texts were screened using the inclusion criteria to filter out irrelevant studies. Data extraction and quality assessment were undertaken using standardized tools and the results were narratively synthesized and presented in tables. Results: Eight studies were included in this systematic review after screening 1191 records. All studies demonstrated a statistically significant reduction in low-density lipoprotein cholesterol (LDL-C) values in the groups that received evolocumab compared with the comparator groups (p < 0.05). The decline in LDL-C levels from baseline in the majority of studies ranged from 40% to 80%, whether used alone or in combination with other agents. Also, high-density lipoprotein cholesterol, lipoprotein (a) and apolipoprotein B were improved with the use of evolocumab. Conclusions: This study helped to collate evidence from studies that tested the effectiveness of evolocumab in the management of hyperlipidemia. Evolocumab seems to be highly effective in reducing LDL-C and other lipid parameters. Hence, it provides an excellent alternative for patients with refractory disease or patients who develop intolerable side effects, therefore helping to overcome the stumbling block to achieving optimal lipid management.",
keywords = "dyslipidemia, evolocumab, hyperlipidemia, proprotein convertase subtilisin/kexin type 9 inhibitors",
author = "Lamia Alhajri and Asma AlHadhrami and Shama AlMheiri and Yalwah AlMutawa and Zainab AlHashimi",
year = "2017",
month = may,
day = "1",
doi = "10.1177/1753944717698925",
language = "English",
volume = "11",
pages = "155--169",
journal = "Therapeutic Advances in Cardiovascular Diseases",
number = "5-6",

}

RIS

TY - JOUR

T1 - The efficacy of evolocumab in the management of hyperlipidemia

T2 - a systematic review

AU - Alhajri, Lamia

AU - AlHadhrami, Asma

AU - AlMheiri, Shama

AU - AlMutawa, Yalwah

AU - AlHashimi, Zainab

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background: Hyperlipidemia or dyslipidemia has been a concern for a long time, with various guidelines emphasizing the importance of managing the lipid profile to prevent cardiac incidences. Although statins have been found to be highly effective, resistance and intolerability to side effects will continue to be a stumbling block for certain patients. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors tackle lipid profile via a novel mechanism and therefore provide an additional effective option for managing lipid profile. The overarching aim of this systematic review was to evaluate the efficacy of evolocumab among various populations with hypercholesterolemia. Methods: A comprehensive search was conducted in ProQuest Health & Medical Complete, Google Scholar, ScienceDirect, and PubMed to identify potential records; then titles, abstracts, and full texts were screened using the inclusion criteria to filter out irrelevant studies. Data extraction and quality assessment were undertaken using standardized tools and the results were narratively synthesized and presented in tables. Results: Eight studies were included in this systematic review after screening 1191 records. All studies demonstrated a statistically significant reduction in low-density lipoprotein cholesterol (LDL-C) values in the groups that received evolocumab compared with the comparator groups (p < 0.05). The decline in LDL-C levels from baseline in the majority of studies ranged from 40% to 80%, whether used alone or in combination with other agents. Also, high-density lipoprotein cholesterol, lipoprotein (a) and apolipoprotein B were improved with the use of evolocumab. Conclusions: This study helped to collate evidence from studies that tested the effectiveness of evolocumab in the management of hyperlipidemia. Evolocumab seems to be highly effective in reducing LDL-C and other lipid parameters. Hence, it provides an excellent alternative for patients with refractory disease or patients who develop intolerable side effects, therefore helping to overcome the stumbling block to achieving optimal lipid management.

AB - Background: Hyperlipidemia or dyslipidemia has been a concern for a long time, with various guidelines emphasizing the importance of managing the lipid profile to prevent cardiac incidences. Although statins have been found to be highly effective, resistance and intolerability to side effects will continue to be a stumbling block for certain patients. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors tackle lipid profile via a novel mechanism and therefore provide an additional effective option for managing lipid profile. The overarching aim of this systematic review was to evaluate the efficacy of evolocumab among various populations with hypercholesterolemia. Methods: A comprehensive search was conducted in ProQuest Health & Medical Complete, Google Scholar, ScienceDirect, and PubMed to identify potential records; then titles, abstracts, and full texts were screened using the inclusion criteria to filter out irrelevant studies. Data extraction and quality assessment were undertaken using standardized tools and the results were narratively synthesized and presented in tables. Results: Eight studies were included in this systematic review after screening 1191 records. All studies demonstrated a statistically significant reduction in low-density lipoprotein cholesterol (LDL-C) values in the groups that received evolocumab compared with the comparator groups (p < 0.05). The decline in LDL-C levels from baseline in the majority of studies ranged from 40% to 80%, whether used alone or in combination with other agents. Also, high-density lipoprotein cholesterol, lipoprotein (a) and apolipoprotein B were improved with the use of evolocumab. Conclusions: This study helped to collate evidence from studies that tested the effectiveness of evolocumab in the management of hyperlipidemia. Evolocumab seems to be highly effective in reducing LDL-C and other lipid parameters. Hence, it provides an excellent alternative for patients with refractory disease or patients who develop intolerable side effects, therefore helping to overcome the stumbling block to achieving optimal lipid management.

KW - dyslipidemia

KW - evolocumab

KW - hyperlipidemia

KW - proprotein convertase subtilisin/kexin type 9 inhibitors

U2 - 10.1177/1753944717698925

DO - 10.1177/1753944717698925

M3 - Journal article

VL - 11

SP - 155

EP - 169

JO - Therapeutic Advances in Cardiovascular Diseases

JF - Therapeutic Advances in Cardiovascular Diseases

IS - 5-6

ER -